drugset / Trial / NCT01323647

Immunogenicity and Safety of Booster Dose of PoliorixTM Vaccine in Previously Vaccinated Toddlers

NCT01323647 ↗

Phase 3 Completed 957 enrolled GlaxoSmithKline
RandomizedParallel-groupOpen-labelPrevention

Summary

This study aims to evaluate the persistence of anti-poliovirus antibodies in toddlers aged 18 months who were primed with oral polio vaccine (OPV) or inactivated polio vaccine (IPV) in the primary study. The study will also assess the immunogenicity and reactogenicity of a booster dose of IPV in subjects primed with three doses of IPV.

Timeline

Start
2011-04-25
Primary completion
2011-09-19
Completion
2011-09-19

Drugs

EvaluationDrugModalityDoseRoute
Subject PoliorixTM Vaccine — Intramuscular
Background Infanrix+Hib Vaccine — Intramuscular

Indications